Chien‐Hsing Chang

5.6k total citations
108 papers, 4.4k citations indexed

About

Chien‐Hsing Chang is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Molecular Biology. According to data from OpenAlex, Chien‐Hsing Chang has authored 108 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Radiology, Nuclear Medicine and Imaging, 43 papers in Oncology and 34 papers in Molecular Biology. Recurrent topics in Chien‐Hsing Chang's work include Monoclonal and Polyclonal Antibodies Research (77 papers), Radiopharmaceutical Chemistry and Applications (46 papers) and Lymphoma Diagnosis and Treatment (19 papers). Chien‐Hsing Chang is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (77 papers), Radiopharmaceutical Chemistry and Applications (46 papers) and Lymphoma Diagnosis and Treatment (19 papers). Chien‐Hsing Chang collaborates with scholars based in United States, Netherlands and France. Chien‐Hsing Chang's co-authors include David M. Goldenberg, Edmund A. Rossi, Robert M. Sharkey, William J. McBride, Thomas M. Cardillo, Habibe Karacay, Hans J. Hansen, Rhona Stein, Serengulam V. Govindan and Christopher D'Souza and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Chien‐Hsing Chang

107 papers receiving 4.3k citations

Peers

Chien‐Hsing Chang

RNMI

ONCOL

IMMUN

PRM

Edmund A. Rossi United States

Thomas M. Cardillo United States

Rhona Stein United States

Serengulam V. Govindan United States

Pamela A. Trail United States

Charles G. Cerveny United States

André Pèlegrin France

Svetlana O. Doronina United States

M. Jules Mattes United States

Che‐Leung Law United States

Edmund A. Rossi United States

Chien‐Hsing Chang

2.9k ×1.0

RNMI

1.8k ×1.0

ONCOL

1.4k ×1.1

627 ×0.8

IMMUN

530 ×1.1

PRM

Citations per year, relative to Chien‐Hsing Chang Chien‐Hsing Chang (= 1×) peers Edmund A. Rossi

Countries citing papers authored by Chien‐Hsing Chang

Since Specialization

Citations

This map shows the geographic impact of Chien‐Hsing Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chien‐Hsing Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chien‐Hsing Chang more than expected).

Fields of papers citing papers by Chien‐Hsing Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chien‐Hsing Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chien‐Hsing Chang. The network helps show where Chien‐Hsing Chang may publish in the future.

Co-authorship network of co-authors of Chien‐Hsing Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Chien‐Hsing Chang. A scholar is included among the top collaborators of Chien‐Hsing Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chien‐Hsing Chang. Chien‐Hsing Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cardillo, Thomas M., Roberto Arrojo, Robert M. Sharkey, et al.. (2024). Sacituzumab govitecan plus platinum-based chemotherapy mediates significant antitumor effects in triple-negative breast, urinary bladder, and small-cell lung carcinomas. Oncotarget. 15(1). 144–158. 9 indexed citations

Chang, Chien‐Hsing, Yang Wang, Rongxiu Li, et al.. (2017). Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells. Cancer Research. 77(19). 5384–5394. 67 indexed citations

Sharkey, Robert M., Serengulam V. Govindan, Thomas M. Cardillo, et al.. (2017). Selective and Concentrated Accretion of SN-38 with a CEACAM5-Targeting Antibody–Drug Conjugate (ADC), Labetuzumab Govitecan (IMMU-130). Molecular Cancer Therapeutics. 17(1). 196–203. 24 indexed citations

Cardillo, Thomas M., Serengulam V. Govindan, Diane L. Rossi, et al.. (2017). IMMU-140, a Novel SN-38 Antibody–Drug Conjugate Targeting HLA-DR, Mediates Dual Cytotoxic Effects in Hematologic Cancers and Malignant Melanoma. Molecular Cancer Therapeutics. 17(1). 150–160. 21 indexed citations

Chang, Chien‐Hsing, et al.. (2016). Combining ABCG2 Inhibitors with IMMU-132, an Anti–Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers. Molecular Cancer Therapeutics. 15(8). 1910–1919. 42 indexed citations

Sharkey, Robert M., William J. McBride, Thomas M. Cardillo, et al.. (2015). Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan). Clinical Cancer Research. 21(22). 5131–5138. 130 indexed citations

Rossi, Edmund A., Diane L. Rossi, Thomas M. Cardillo, Chien‐Hsing Chang, & David M. Goldenberg. (2014). Redirected T-Cell Killing of Solid Cancers Targeted with an Anti-CD3/Trop-2–Bispecific Antibody Is Enhanced in Combination with Interferon-α. Molecular Cancer Therapeutics. 13(10). 2341–2351. 20 indexed citations

Rossi, Edmund A., Chien‐Hsing Chang, & David M. Goldenberg. (2014). Anti-CD22/CD20 Bispecific Antibody with Enhanced Trogocytosis for Treatment of Lupus. PLoS ONE. 9(5). e98315–e98315. 29 indexed citations

Rossi, Edmund A., David M. Goldenberg, Rosana Michel, et al.. (2013). Trogocytosis of multiple B-cell surface markers by CD22 targeting with epratuzumab. Blood. 122(17). 3020–3029. 88 indexed citations

10.

Salaün, Pierre‐Yves, L. Campion, Claire Bournaud, et al.. (2012). Phase II Trial of Anticarcinoembryonic Antigen Pretargeted Radioimmunotherapy in Progressive Metastatic Medullary Thyroid Carcinoma: Biomarker Response and Survival Improvement. Journal of Nuclear Medicine. 53(8). 1185–1192. 44 indexed citations

11.

Schoffelen, Rafke, Winette T.A. van der Graaf, Robert M. Sharkey, et al.. (2012). Quantitative Immuno-SPECT Monitoring of Pretargeted Radioimmunotherapy with a Bispecific Antibody in an Intraperitoneal Nude Mouse Model of Human Colon Cancer. Journal of Nuclear Medicine. 53(12). 1926–1932. 11 indexed citations

12.

Rossi, Edmund A., Diane L. Rossi, Rhona Stein, David M. Goldenberg, & Chien‐Hsing Chang. (2010). A Bispecific Antibody-IFNα2b Immunocytokine Targeting CD20 and HLA-DR Is Highly Toxic to Human Lymphoma and Multiple Myeloma Cells. Cancer Research. 70(19). 7600–7609. 39 indexed citations

13.

Chang, Chien‐Hsing, Pankaj Gupta, Rosana Michel, et al.. (2010). Ranpirnase (Frog RNase) Targeted with a Humanized, Internalizing, Anti–Trop-2 Antibody Has Potent Cytotoxicity against Diverse Epithelial Cancer Cells. Molecular Cancer Therapeutics. 9(8). 2276–2286. 43 indexed citations

14.

Sharkey, Robert M., Edmund A. Rossi, Chien‐Hsing Chang, & David M. Goldenberg. (2010). Improved Cancer Therapy and Molecular Imaging with Multivalent, Multispecific Antibodies. Cancer Biotherapy and Radiopharmaceuticals. 25(1). 1–12. 16 indexed citations

15.

Rossi, Edmund A., David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, & Chien‐Hsing Chang. (2009). CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. 114(18). 3864–3871. 57 indexed citations

16.

Sharkey, Robert M., Habibe Karacay, Samuel Litwin, et al.. (2008). Improved Therapeutic Results by Pretargeted Radioimmunotherapy of Non–Hodgkin's Lymphoma with a New Recombinant, Trivalent, Anti-CD20, Bispecific Antibody. Cancer Research. 68(13). 5282–5290. 60 indexed citations

17.

Gold, David V., David M. Goldenberg, Habibe Karacay, et al.. (2008). A Novel Bispecific, Trivalent Antibody Construct for Targeting Pancreatic Carcinoma. Cancer Research. 68(12). 4819–4826. 53 indexed citations

18.

Rossi, Edmund A., David M. Goldenberg, Thomas M. Cardillo, et al.. (2008). Novel Designs of Multivalent Anti-CD20 Humanized Antibodies as Improved Lymphoma Therapeutics. Cancer Research. 68(20). 8384–8392. 49 indexed citations

19.

Chang, Chien‐Hsing, et al.. (2008). A modular method to prepare novel tetrameric cytokines, IFN, G-CSF, and EPO, with improved pharmacokinetics by the Dock-and-Lock (DNL) platform technology. Cancer Research. 68. 4906–4906. 2 indexed citations

20.

Sapra, Puja, et al.. (2005). Construction, characterization, and mammalian expression of an immunotoxin consisting of ranpirnase (Rap) fused to a humanized anti-EGP-1 antibody, hRS7, as a potential therapeutic for prostate cancer. Cancer Research. 65. 160–160. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact